Concord Medical Services Holdings Limited CCM
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -0.26%
- 1 year
- -30.00%
- Market cap
- 16.72M
- Revenue (ttm)
- 471.70M
- Profit margin
- -80.33%
- EPS (ttm)
- -2.96
- Shares out
- 2.82M
- Forward P/E
- -30.00
- YTD return
- -0.26%
- 1-year return
- -30.00%
- Volume
- 61.70K
- Avg volume
- 44.90K
- Open
- 3.39
- Previous close
- 3.59
- Day's range
- 3.39 – 4.01
- 52-week range
- 2.79 – 6.80
- Beta
- -0.27
- Earnings date
- Apr 29, 2019
3M -0.91 (-19.78%)
Key statistics
- Enterprise value
- 7.88B
- PEG ratio
- 0.00
- Price / sales
- 0.04
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -23.10%
- Free cash flow
- 0
- Total cash
- 326.90M
- Total debt
- 3.56B
- Return on equity
- -32.40%
- Short % of float
- 0.00%
- 50-day average
- 5.90
- 200-day average
- 6.53
Next earnings
Apr 29, 2019
Expected Apr 29, 2019. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Apr 29, 2019 | Dec 1, 2018 | 0.01 | — | — | — |
| May 7, 2018 | Dec 1, 2017 | -0.06 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 23, 2012 | Morgan Stanley | main | — | Overweight |
| Jul 6, 2012 | Morgan Stanley | main | — | Overweight |
| Mar 22, 2012 | JP Morgan | main | — | Overweight |
About Concord Medical Services Holdings Limited
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Country
- China
- Website
- concordmedical.com
News
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
Cohen & Company Capital Markets Launches Private Credit Advisory Practice
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
TWO Urges Stockholders to Vote FOR the CCM Transaction Today; Failure to Approve Risks a Significant Decline in TWO's Stock Price
ComplianceCow to Demonstrate Generative AI-Powered CCM 3.0 Controls in ServiceNow IRM
RegScale Achieves ISO 27001 Certification in Under 30 Days Using Its Own Continuous Controls Monitoring Platform
Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services
Concord Medical Files Annual Report on Form 20-F for the Fiscal Year 2025
Your note
Sign in to keep a note on CCM — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Rhumbline Advisers | 0.09% | 2,460 | 11.07K | Sep 29, 2024 |
| UBS Group AG | 0.03% | 923 | 4.15K | Sep 29, 2024 |
